drugset / Trial / NCT05368545
Influence of Lipid Lowering on Impaired Coronary Flow
RandomizedParallel-groupOpen-labelOther
Summary
This study assess in patients with stable chest pain and coronary artery disease (CAD) determined by coronary CTA whether cholesterol lowering with regression of coronary adverse plaque characteristics is associated with recovery of impaired flow
Timeline
- Start
- 2020-05-15
- Primary completion
- 2024-04-17
- Completion
- 2024-04-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atorvastatin | Small molecule | 40 mg | — |
| Subject | Ezetimibe | Unknown | 10 mg | — |
| Subject | Rosuvastatin | Small molecule | 40 mg | — |